JPWO2023001303A5 - - Google Patents
Info
- Publication number
- JPWO2023001303A5 JPWO2023001303A5 JP2024503607A JP2024503607A JPWO2023001303A5 JP WO2023001303 A5 JPWO2023001303 A5 JP WO2023001303A5 JP 2024503607 A JP2024503607 A JP 2024503607A JP 2024503607 A JP2024503607 A JP 2024503607A JP WO2023001303 A5 JPWO2023001303 A5 JP WO2023001303A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110842497 | 2021-07-23 | ||
| CN202110842497.1 | 2021-07-23 | ||
| PCT/CN2022/107522 WO2023001303A1 (zh) | 2021-07-23 | 2022-07-22 | 药物组合物及用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024528682A JP2024528682A (ja) | 2024-07-30 |
| JP2024528682A5 JP2024528682A5 (https=) | 2025-07-31 |
| JPWO2023001303A5 true JPWO2023001303A5 (https=) | 2025-07-31 |
Family
ID=84978972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503607A Pending JP2024528682A (ja) | 2021-07-23 | 2022-07-22 | 薬物組成物及び用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240352153A1 (https=) |
| EP (1) | EP4375300A4 (https=) |
| JP (1) | JP2024528682A (https=) |
| KR (1) | KR20240038043A (https=) |
| CN (1) | CN116059341A (https=) |
| AU (1) | AU2022314097A1 (https=) |
| CA (1) | CA3226242A1 (https=) |
| IL (1) | IL310217A (https=) |
| MX (1) | MX2024001067A (https=) |
| WO (1) | WO2023001303A1 (https=) |
| ZA (1) | ZA202400787B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020324185A1 (en) * | 2019-08-02 | 2022-03-03 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | Anti-PD-1 antibody and medical use thereof |
| AU2021372706A1 (en) * | 2020-10-26 | 2023-06-08 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| JP2026508210A (ja) * | 2023-02-20 | 2026-03-10 | 中山康方生物医▲藥▼有限公司 | ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用 |
| CN121398845A (zh) * | 2023-07-14 | 2026-01-23 | 嘉和生物药业有限公司 | 抗pd-1/ctla-4/tigit三特异性抗体及其用途 |
| WO2025201450A1 (zh) * | 2024-03-27 | 2025-10-02 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
| WO2025232896A1 (zh) * | 2024-05-10 | 2025-11-13 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| US10323095B2 (en) | 2014-03-17 | 2019-06-18 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| CN107207594B (zh) * | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CA2994858C (en) | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| JP7402693B2 (ja) * | 2017-05-02 | 2023-12-21 | メルク・シャープ・アンド・ドーム・エルエルシー | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| US20210340250A1 (en) * | 2017-05-30 | 2021-11-04 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| CN109384846B (zh) * | 2018-09-25 | 2020-03-03 | 合肥瑞达免疫药物研究所有限公司 | 能够结合tigit的抗体或其抗原结合片段及用途 |
| BR112021012027A2 (pt) * | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula bifuncional direcionada contra pd-1 humano |
| CN111744013B (zh) * | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 |
| WO2021023117A1 (zh) | 2019-08-02 | 2021-02-11 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| CN114641502B (zh) * | 2019-11-14 | 2023-11-14 | 上海药明生物技术有限公司 | 一种新的抗tigit抗体 |
| AU2021372706A1 (en) * | 2020-10-26 | 2023-06-08 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| CN112794909B (zh) * | 2021-02-04 | 2022-06-14 | 广州爱思迈生物医药科技有限公司 | 一种抗tigit单克隆抗体及其应用 |
| CN114106182B (zh) * | 2022-01-26 | 2022-05-17 | 中山康方生物医药有限公司 | 抗tigit的抗体及其用途 |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
-
2022
- 2022-07-22 IL IL310217A patent/IL310217A/en unknown
- 2022-07-22 CN CN202210875610.0A patent/CN116059341A/zh active Pending
- 2022-07-22 JP JP2024503607A patent/JP2024528682A/ja active Pending
- 2022-07-22 KR KR1020247006091A patent/KR20240038043A/ko active Pending
- 2022-07-22 US US18/291,128 patent/US20240352153A1/en active Pending
- 2022-07-22 EP EP22845466.6A patent/EP4375300A4/en active Pending
- 2022-07-22 AU AU2022314097A patent/AU2022314097A1/en active Pending
- 2022-07-22 WO PCT/CN2022/107522 patent/WO2023001303A1/zh not_active Ceased
- 2022-07-22 MX MX2024001067A patent/MX2024001067A/es unknown
- 2022-07-22 CA CA3226242A patent/CA3226242A1/en active Pending
-
2024
- 2024-01-23 ZA ZA2024/00787A patent/ZA202400787B/en unknown